A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma
Phase 2
Withdrawn
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Combination Product: Aliya Pulse Electric Field sysem and pembrolizumab
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06494787
Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures
Withdrawn
- Conditions
- Sarcoma
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Registration Number
- NCT05869994
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Phase 2
Recruiting
- Conditions
- Sarcoma
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 260
- Registration Number
- NCT04535713
- Locations
- 🇺🇸
Sant P Chawla, Santa Monica, California, United States
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT04535271
- Locations
- 🇺🇸
Sant P Chawla, Santa Monica, California, United States
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Small Cell Lung CancerSolid Tumor, AdultSoft Tissue SarcomaNon Small Cell Lung Cancer
- Interventions
- Drug: AL3818
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 56
- Registration Number
- NCT04165330
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Phase 2
Recruiting
- Conditions
- Sarcoma
- Interventions
- Drug: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT03886311
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma
Phase 2
Active, not recruiting
- Conditions
- Sarcoma, EwingSarcoma
- Interventions
- Drug: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT03778996
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Phase 1
Completed
- Conditions
- Ewing SarcomaPEComaEpithelioid SarcomaDesmoid TumorChordomaNon Small Cell Lung CancerUrothelial CarcinomaMelanomaRenal Cell CarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT03190174
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Phase 1
Recruiting
- Conditions
- Metastatic Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT03138161
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
© Copyright 2025. All Rights Reserved by MedPath